Table 3.
Univariate analysis of clinicopathological factors and survival time of prostate cancer patients of ≤55 years.
| Predictor | Median survival (95%CI) (mo) | χ2 | P value |
|---|---|---|---|
| PSA | 0.016 | 0.899 | |
| <20 ng/ml(n=31) | 59 (27.5–90.5) | ||
| ≥20 ng/ml(n=75) | 52 (41.0–63.0) | ||
| CCI score | 0.045 | 0.832 | |
| 0 (n=90) | 54 (40.9–67.1) | ||
| ≥1 (n=16) | 44 (35.4–52.6) | ||
| T staging | 31.789 | <0.001 | |
| T2 (n=28) | 91 (70.1–111.9) | ||
| T3 (n=45) | 52 (39.1–64.9) | ||
| T4 (n=29) | 26 (18.0–34.0) | ||
| Lymphatic metastasis | 3.141 | 0.076 | |
| Absent (n=66) | 57 (40.1–73.9) | ||
| Present (n=40) | 37 (33.7–40.3) | ||
| Osseous metastasis | 0.051 | 0.822 | |
| Absent (n=50) | 54 (43.6–64.4) | ||
| Present (n=56) | 45 (37.1–52.9) | ||
| Visceral metastasis | 11.641 | 0.001 | |
| Absent (n=86) | 57 (48.3–65.7) | ||
| Present (n=20) | 28 (16.2–39.8) | ||
| Pathological pattern | 23.159 | <0.001 | |
| Acinous carcinoma (n=94) | 55 (44.6–65.4) | ||
| Non-acinus carcinoma(n=12) | 10 (5.0–15.0) | ||
| Gleason sum | 18.364 | <0.001 | |
| 2–6 (n=10) | 100 (5.5–194.5) | ||
| 7 (n=22) | 60 (32.5–87.5) | ||
| 8–10 (n=69) | 40 (32.6–47.4) | ||
| Local therapy | |||
| Without(n=62) | 45 (35.9–54.1) | 7.274 | 0.007 |
| With(n=44) | 73 (42.4–103.6) |